[go: up one dir, main page]

UA87665C2 - Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis - Google Patents

Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis

Info

Publication number
UA87665C2
UA87665C2 UAA200601775A UAA200601775A UA87665C2 UA 87665 C2 UA87665 C2 UA 87665C2 UA A200601775 A UAA200601775 A UA A200601775A UA A200601775 A UAA200601775 A UA A200601775A UA 87665 C2 UA87665 C2 UA 87665C2
Authority
UA
Ukraine
Prior art keywords
vaccine
lawsonia intracellularis
producing
avirulent isolate
avirulent
Prior art date
Application number
UAA200601775A
Other languages
English (en)
Ukrainian (uk)
Inventor
Майкл Б. Руфф
Джереми Дж. Кроулл
Джеффри П. Ниттел
Original Assignee
Берингер Ингельхайм Ветмедика, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34115340&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA87665(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Берингер Ингельхайм Ветмедика, Инк. filed Critical Берингер Ингельхайм Ветмедика, Инк.
Publication of UA87665C2 publication Critical patent/UA87665C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/825—Bacterial vaccine for porcine species, e.g. swine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Изобретение относится к авирулентному изоляту, где авирулентный изолят представляет собой изолят, депонируемый под регистрационным номером ATCC PTA-4926, или какому-либо авирулентному изолятуевропейского происхождения, который отличается тем, что указанный авирулентный изолятне выделяется с фекалиями на 14 день после вакцинации. Также изобретение относится к вакцине для иммунизации животного, которая содержит фармацевтически эффективное количество авирулентногои фармацевтически приемлемый носитель. Кроме того, изобретение относится к применению заявленного авирулентного изолята как вакцины, способа получения указанной вакцины для индукции иммунного ответа на бактерииу животного, способа культивированияспособа диагностики пролиферативной энтеропатии свиней и способа получения антисыворотки кв организме животного, �
UAA200601775A 2003-07-25 2004-07-15 Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis UA87665C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49000103P 2003-07-25 2003-07-25

Publications (1)

Publication Number Publication Date
UA87665C2 true UA87665C2 (ru) 2009-08-10

Family

ID=34115340

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200601775A UA87665C2 (ru) 2003-07-25 2004-07-15 Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis

Country Status (23)

Country Link
US (2) US7312065B2 (ru)
EP (1) EP1651260B2 (ru)
JP (1) JP2006528882A (ru)
KR (1) KR101131845B1 (ru)
CN (2) CN1829529B (ru)
AT (1) ATE442163T2 (ru)
AU (1) AU2004260657B2 (ru)
BR (1) BRPI0412911B1 (ru)
CA (1) CA2533559C (ru)
CY (1) CY1109652T1 (ru)
DE (1) DE602004023094D1 (ru)
DK (1) DK1651260T4 (ru)
ES (1) ES2333334T5 (ru)
MX (1) MXPA06000994A (ru)
MY (1) MY140208A (ru)
PL (1) PL1651260T5 (ru)
PT (1) PT1651260E (ru)
RU (1) RU2420570C2 (ru)
SG (1) SG144909A1 (ru)
SI (1) SI1651260T2 (ru)
UA (1) UA87665C2 (ru)
WO (1) WO2005011731A1 (ru)
ZA (1) ZA200510081B (ru)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
AU2012207016B2 (en) * 2005-03-14 2015-01-15 Boehringer Ingelheim Animal Health USA Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
PT3127551T (pt) * 2005-12-29 2020-10-09 Boehringer Ingelheim Animal Health Usa Inc Composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
PL1968630T3 (pl) 2005-12-29 2018-08-31 Boehringer Ingelheim Vetmedica, Inc. Multiwalentne immunogenne kompozycje PCV2
US8470336B2 (en) * 2006-05-25 2013-06-25 Boehringer Ingelheim Vetmedica, Inc. Vaccination of young animals against Lawsonia intracellularis infections
US20080241190A1 (en) * 2006-11-13 2008-10-02 Boehringer Ingelheim Vetmedica, Inc. Vaccination of horses against lawsonia intracellularis
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (en) 2006-12-11 2015-04-15 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
CN101558169B (zh) * 2006-12-15 2017-08-04 贝林格尔.英格海姆维特梅迪卡有限公司 以pcv2抗原治疗猪
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
TW200918666A (en) * 2007-09-11 2009-05-01 Wyeth Corp Attenuated mycoplasma gallisepticum strains
WO2009037262A2 (en) 2007-09-17 2009-03-26 Boehringer Ingelheim Vetmedica, Inc. Method of preventing early lawsonia intracellularis infections
JP2011508595A (ja) * 2007-12-31 2011-03-17 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 外来性アミノ酸の挿入を含むｐｃｖ２ｏｒｆ２ウイルス様粒子
EP2242511A4 (en) * 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
TWI449533B (zh) * 2008-04-18 2014-08-21 Intervet Int Bv 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａ ｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅ ｃｉｒｃｏ ｖｉｒｕｓ）用疫苗
TWI551295B (zh) 2008-04-18 2016-10-01 英特威特國際股份有限公司 防備胞內勞森菌（Ｌａｗｓｏｎｉａ ｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）用疫苗
ES2534556T3 (es) 2008-07-22 2015-04-24 Intervet International Bv Bacteria Lawsonia intracellularis de un nuevo serotipo, vacuna basada en esa bacteria, anticuerpos adecuados para diagnosticar el nuevo serotipo de Lawsonia intracellularis e hibridomas para producir dichos anticuerpos
US8142760B2 (en) * 2008-09-05 2012-03-27 Nathan Len Winkelman Vaccination for Lawsonia intracellularis
WO2011006880A1 (en) * 2009-07-14 2011-01-20 Intervet International B.V. Lawsonia intracellularis propagation
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
EP2499233B1 (en) 2009-11-09 2016-11-02 Intervet International B.V. Method to grow lawsonia intracellularis bacteria in persistently infected mccoy cells
ES2625406T3 (es) 2010-03-25 2017-07-19 Oregon Health & Science University Glicoproteínas de CMV y vectores recombinantes
WO2012170765A2 (en) 2011-06-10 2012-12-13 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
EP4091629A1 (en) 2013-09-25 2022-11-23 Zoetis Services LLC Pcv2b divergent vaccine composition and methods of use
KR102409183B1 (ko) 2013-10-02 2022-06-15 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Ｐｃｖ2 ｏｒｆ2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
US10130699B2 (en) 2013-12-03 2018-11-20 Intervet Inc. Vaccine against Lawsonia intracellularis and porcine circovirus 2
CN103823063B (zh) * 2014-02-25 2015-09-30 上海理工大学 检测猪霍乱沙门氏菌的方法及其单抗
RU2709197C2 (ru) 2015-02-04 2019-12-17 Интервет Интернэшнл Б.В. Вакцина для применения против субклинической инфекции lawsonia у свиней
KR101893827B1 (ko) * 2016-01-04 2018-08-31 전북대학교 산학협력단 약독화된 살모넬라 변이주를 유효성분으로 포함하는 돼지 증식성 회장염 및 살모넬라증 동시 예방 또는 치료용 백신 조성물
CA3088651A1 (en) * 2018-02-28 2019-09-06 Boehringer Ingelheim Vetmedica Gmbh Method for reducing skatole and/or indole in animals
KR102249189B1 (ko) * 2020-01-09 2021-05-07 전북대학교 산학협력단 항원성이 증진된 항원을 발현하는 약독화된 살모넬라 변이주를 유효성분으로 포함하는 돼지 증식성 회장염 및 살모넬라증 동시 예방 또는 치료용 백신 조성물
BR112023001324A2 (pt) * 2020-07-24 2023-02-14 Boehringer Ingelheim Animal Health Usa Inc Combinação de vacina de suíno
CN111961627A (zh) * 2020-08-27 2020-11-20 南京农业大学 一种胞内劳森菌的分离与培养方法
US12409212B2 (en) 2021-11-01 2025-09-09 Boehringer Ingelheim Vetmedica Gmbh Immunogenic gel compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5885823A (en) † 1995-06-05 1999-03-23 Nobl Laboratories, Inc. Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
US5714375A (en) * 1995-06-05 1998-02-03 Nobl Laboratories, Inc. Ileal symbiont intracellularis propagation in suspended host cells

Also Published As

Publication number Publication date
BRPI0412911A (pt) 2006-09-26
SI1651260T1 (sl) 2010-01-29
MY140208A (en) 2009-11-30
CN1829529B (zh) 2011-05-04
WO2005011731A1 (en) 2005-02-10
AU2004260657A1 (en) 2005-02-10
PL1651260T5 (pl) 2018-11-30
DK1651260T4 (en) 2018-10-08
ES2333334T3 (es) 2010-02-19
EP1651260B2 (en) 2018-06-27
US20080112980A1 (en) 2008-05-15
MXPA06000994A (es) 2006-05-15
ES2333334T5 (es) 2018-08-06
US7312065B2 (en) 2007-12-25
EP1651260A1 (en) 2006-05-03
CN1829529A (zh) 2006-09-06
KR20060054352A (ko) 2006-05-22
KR101131845B1 (ko) 2012-03-30
CA2533559C (en) 2013-07-02
BRPI0412911B1 (pt) 2020-01-21
SG144909A1 (en) 2008-08-28
DE602004023094D1 (de) 2009-10-22
US7758870B2 (en) 2010-07-20
DK1651260T3 (da) 2010-01-11
CN101423811A (zh) 2009-05-06
RU2006105715A (ru) 2007-09-10
ATE442163T2 (de) 2009-09-15
AU2004260657B2 (en) 2012-06-07
JP2006528882A (ja) 2006-12-28
CA2533559A1 (en) 2005-02-10
CY1109652T1 (el) 2014-08-13
SI1651260T2 (sl) 2018-09-28
EP1651260B1 (en) 2009-09-09
US20050031647A1 (en) 2005-02-10
ZA200510081B (en) 2006-08-30
PL1651260T3 (pl) 2010-02-26
PT1651260E (pt) 2009-09-24
RU2420570C2 (ru) 2011-06-10

Similar Documents

Publication Publication Date Title
UA87665C2 (ru) Авирулентный изолят lawsonia intracellularis европейского происхождения, вакцина для иммунизации животных, применение заявленного авирулентного изолята как вакцины, способ получения вакцины, способ культивирования lawsonia intracellularis, способ диагностики пролиферативной энтеропатии свиней и способ получения антисыворотки к lawsonia intracellularis
US11103569B2 (en) Vaccine for protection against Streptococcus suis
EP0822830A4 (en) HUMAN ANTIBODIES FROM IMMUNIZED XENOMAS
PL346299A1 (en) Method of dna vaccination
Wang et al. Research progress in live attenuated Brucella vaccine development
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
MX9303992A (es) Mutantes de eliminacion como vacunas para el colera.
US20150328301A1 (en) Glycoconjugate vaccines
Liao et al. Immunogenicity and efficacy of three recombinant subunit Pasteurella multocida toxin vaccines against progressive atrophic rhinitis in pigs
MacLeod et al. Immunization of pigs with a purified Shiga-like toxin II variant toxoid
Guy et al. Comparison between targeted and untargeted systemic immunizations with adjuvanted urease to cure Helicobacter pylori infection in mice
Joshi et al. Comparative immunogenicity and protective efficacy of different preparations of outer membrane proteins of Pasteurella multocida (B: 2) in a mouse model
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
MX395464B (es) Composicion de lhrh inmunogenica y uso de la misma en cerdos.
JP6148671B2 (ja) 腫瘍抗原を保有する微生物
AR023975A1 (es) Nuevo gen lawsonia spp. y sus usos v
NZ515330A (en) Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses
Vinitnantharat et al. Isolation and purification of an outer membrane protein of Edwardsiella ictaluri and its antigenicity to channel catfish (Ictalurus punctatus)
Ramezanalizadeh et al. Evaluation of hyperimmune colostrum production in bovine against cariogenic streptococci and its impact on growth and bacterial biofilm formation
US7732580B2 (en) Compositions for eliciting an immune response against Mycobacterium avium subspecies paratuberculosis
IL122829A0 (en) Isolated strains of staphylococcus aureus and vaccines manufactured therefrom
Siadat et al. Biological and immunological characteristics of Brucella abortus S99 major outer membrane proteins
WO2007052238A3 (en) Chimeric antigens and vaccines
WO2004043286A3 (en) Use of rmlt as a marker antigen for vaccines and as a synergistic adjuvant with amphigen
Serrano et al. Comparison of IgM, IgG1 and IgG2 responses to Trichinella spiralis and Trichinella britovi in swine